Details of the Drug
General Information of Drug (ID: DMH7FC9)
Drug Name |
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; CDPPB; 781652-57-1; mGluR5 Ligand, CDPPB; CHEMBL190270; GTPL1422; SCHEMBL1823352; CTK5E5464; DTXSID80459996; MolPort-009-199-287; ZINC3986698; BDBM50156071; IN1239; AKOS024457497; RTC-070344; NCGC00370800-01; KB-75992; EN002594; TC-070344; DB-075421; FT-0763465; B7324; A9858; 3-cyano-N-[2,5-di(phenyl)pyrazol-3-yl]benzamide; 3-Cyano-N-1,3-diphenyl-1H-pyrazol-5-yl)benzamide
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 364.4 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 4.4 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References